Regulatory

Face-to-face meetings will now include in-person and virtual components.

Agency panel backs the use of a common bivalent shot for all patients.

21st Century Cures Act prompts FDA to harmonize regulations.

EMA reminds the clinical trials community that the Clinical Trials Information System will be mandatory at the last day of this month.

The issues engulfing compliance with the Clinical Trials Regulation signal that even the best intentions with these types of laws may not be enough to avert unintended consequences.

Webinar Date/Time: Tue, Feb 21, 2023 11:00 AM EST

Latest recommendation places great emphasis on patients.

WHO in midst of forming group focused on developing guidance on best practices in clinical trials.

House report on Aduhelm approval calls for FDA to clarify its role in advising sponsors on drug testing and submissions.

Despite agreement on recommendations between European regulators, DCT unclarity remains.

The Consolidated Appropriations Act for 2023 includes dozens of measures involving drug development and regulation.

Michelle Webb, vice president of the WCG Avoca Quality Consortium, discusses her perspectives on FDA's revised overview of inspection activities.

Insights from second annual DTRA meeting indicate DCTs are here to stay.

Automating process can reduce time and resources lost from using manual steps and allows stakeholders to maintain compliance.

A roadmap to avoiding the common pitfalls of concurrent FDA-EMA filings.

Summarizing important FDA and EMA revisions issued this year.

Navigating FDA’s draft guidance and heightened diversity recommendations.

Debates caught between focusing on existing antibiotics and developing new agents.

Looking back on major FDA moves in 2022.

Marci Macpherson, executive director, quality assurance and compliance at Ionis Pharmaceuticals, discusses her perspectives on inspection readiness.

Inaugural group of members added to EMA’s new data network focused on RWE.

New guidance to drill down on more specifics in hopes of harnessing the growth of these types of studies.

Following closely contested election, approval of FDA bills most likely tabled until new year.